# Autolus Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/autolus-therapeutics

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.autolus.com
- Total disclosed funding: $180M
- Latest round: Series C (Sep 26, 2017)
- Investors on record: 6

## About

Founded in 2014 by Martin Pule and based in London, UK, Autolus Therapeutics plc  operates in two geographic regions, the United Kingdom and the United States. Autolus works with research institutions and business partners to create and distribute programmed T cell product candidates to patients. The company raised its first funding in January 2015 for GBP 30 million. In February 2021, Autolus Therapeutics plc raised USD 100 million in PIPE funding and in November 2021, Autolus Therapeutics plc raised USD 250 million in PIPE funding from new investor Blackstone Group.

The company's technology offers to reprogram T-cells into targeting tumor cells in cancer patients. The company's clinical-stage pipeline comprises five programs: AUTO1, AUTO1/22, AUTO3, AUTO4, and AUTO6. AUTO1 was published in Nature Medicine. AUTO2 is a two-targeted programmed T cell therapy used to treat relapsed or refractory multiple myeloma. AUTO3 is a dual-targeting programmed T cell therapy used to treat relapsed or refractory DLBCL. AUTO4 is a programmed T cell therapy that is used to treat peripheral T-cell lymphoma. AUTO6 is a programmed T cell therapy that is used to treat neuroblastoma.

The company plans to use the funds for the advancement of its obecabtagene autoleucel.

## Funding rounds

- Series C, Sep 26, 2017, $79M — Nextech, Syncona, University College London Business, Cormorant Asset Management, Woodford Patient Capital Trust, Arix Bioscience
- Series B, Mar 3, 2016, $56M — Woodford Patient Capital Trust, Arix Bioscience
- Series A, Jan 22, 2015, $46M — Syncona

## Investors

- Syncona (https://capitalatlas.ai/funds/syncona) — Series A, Series C
- Woodford Patient Capital Trust — Series B, Series C
- Arix Bioscience (https://capitalatlas.ai/funds/arix-bioscience) — Series B, Series C
- Nextech (https://capitalatlas.ai/funds/nextech) — Series C
- University College London Business — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C